Longaeva Partners L.P. Akebia Therapeutics, Inc. Transaction History
Longaeva Partners L.P.
- $490 Billion
- Q2 2025
A detailed history of Longaeva Partners L.P. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Longaeva Partners L.P. holds 191,691 shares of AKBA stock, worth $594,242. This represents 0.14% of its overall portfolio holdings.
Number of Shares
191,691
Previous 500,000
61.66%
Holding current value
$594,242
Previous $960 Million
27.32%
% of portfolio
0.14%
Previous 0.54%
Shares
2 transactions
Others Institutions Holding AKBA
# of Institutions
173Shares Held
106MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$45.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$36.1 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$24.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$18.8 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$17.8 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $570M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...